Skip to main content
Erschienen in:

24.02.2022 | original article

Evaluation of ocular manifestations in Parkinson disease and their change during a 2-year follow-up

verfasst von: Mark Rabinovich, MD, Kevin Gillmann, MD MBBS, FEBOphth, March, Ulla Birk, MD, Nir Shoham-Hazon, MD, Jean-Marc Baumgartner, MD

Erschienen in: Spektrum der Augenheilkunde | Ausgabe 5/2023

Einloggen, um Zugang zu erhalten

Summary

Aim

The aim of the present study was to evaluate ocular changes in patients with Parkinson disease (PD) and discuss the potential impact of these changes on glaucoma management.

Methods

This was a single-center, retrospective study, evaluating 60 eyes of 60 patients. The study population was divided into two groups: a PD group comprising 33 eyes compared with a healthy control group of 27 eyes. We evaluated best-corrected visual acuity, central corneal thickness (CCT), mean retinal nerve fiber layer (RNFL) thickness, intraocular pressure span, and type of glaucoma.

Results

Pachymetric measurements of CCT were not significantly reduced in the PD group compared to the control group: 547.3 ± 31.2 μm vs. 531.47 ± 34.5 μm, p > 0.05, respectively. The most prevalent type of glaucoma was open-angle glaucoma, with a rate of 12% in the PD group versus 18% in the control group. Normal-pressure glaucoma was the second most prevalent type at a rate of 9% and 15%, respectively, while the rate for pseudoexfoliation (PEX) glaucoma was 9% versus 11%, respectively. There was no significant difference between groups in the number of anti-glaucoma medications per patient, RNFL thickness and its trend, or mean deviation. Treatment of PD, adjusted for age and sex, had a significant correlation with CCT reduction (r = 0.5, R2 = 25% p < 0.05).

Conclusion

The study findings suggest there is a tendency toward a reduction in CCT with age as PD progresses.
Literatur
1.
Zurück zum Zitat Pringsheim T, Fiest K, Jette N, et al. The international incidence and prevalence of neurologic conditions: how common are they? Neurology. 2014;83:1661–4.CrossRefPubMedPubMedCentral Pringsheim T, Fiest K, Jette N, et al. The international incidence and prevalence of neurologic conditions: how common are they? Neurology. 2014;83:1661–4.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Archibald NK, Clarke MP, Mosimann UP, et al. Visual symptoms in Parkinson’s disease and Parkinson’s disease dementia. Mov Disord. 2011;26:2387–95.CrossRefPubMed Archibald NK, Clarke MP, Mosimann UP, et al. Visual symptoms in Parkinson’s disease and Parkinson’s disease dementia. Mov Disord. 2011;26:2387–95.CrossRefPubMed
3.
Zurück zum Zitat Uc EY, Rizzo M, Anderson SW, Qian S, Rodnitzky RL, Dawson JD. Visual dysfunction in Parkinson disease without dementia. Neurology. 2005;65:1907–13.CrossRefPubMed Uc EY, Rizzo M, Anderson SW, Qian S, Rodnitzky RL, Dawson JD. Visual dysfunction in Parkinson disease without dementia. Neurology. 2005;65:1907–13.CrossRefPubMed
9.
Zurück zum Zitat Hernowo AT, Boucard CC, Jansonius NM, et al. Automated morphometry of the visual pathway in primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2011;25(52):2758–66.CrossRef Hernowo AT, Boucard CC, Jansonius NM, et al. Automated morphometry of the visual pathway in primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2011;25(52):2758–66.CrossRef
14.
Zurück zum Zitat Yenice O, Onal S, Midi I, Ozcan E, Temel A, I‑Gunal D. Visual field analysis in patients with Parkinson’s disease. Parkinson Relat Disord. 2008;14:193–8.CrossRef Yenice O, Onal S, Midi I, Ozcan E, Temel A, I‑Gunal D. Visual field analysis in patients with Parkinson’s disease. Parkinson Relat Disord. 2008;14:193–8.CrossRef
15.
Zurück zum Zitat Lin I‑C, Wang Y‑H, Wang T‑J, et al. Glaucoma, Alzheimer’s Disease, and Parkinson’s Disease: An 8‑Year Population-Based Follow-Up Study. Plos One. 2014;9:e108938.CrossRefPubMedPubMedCentral Lin I‑C, Wang Y‑H, Wang T‑J, et al. Glaucoma, Alzheimer’s Disease, and Parkinson’s Disease: An 8‑Year Population-Based Follow-Up Study. Plos One. 2014;9:e108938.CrossRefPubMedPubMedCentral
Metadaten
Titel
Evaluation of ocular manifestations in Parkinson disease and their change during a 2-year follow-up
verfasst von
Mark Rabinovich, MD
Kevin Gillmann, MD MBBS, FEBOphth, March
Ulla Birk, MD
Nir Shoham-Hazon, MD
Jean-Marc Baumgartner, MD
Publikationsdatum
24.02.2022
Verlag
Springer Vienna
Erschienen in
Spektrum der Augenheilkunde / Ausgabe 5/2023
Print ISSN: 0930-4282
Elektronische ISSN: 1613-7523
DOI
https://doi.org/10.1007/s00717-022-00516-x

Weitere Artikel der Ausgabe 5/2023

Spektrum der Augenheilkunde 5/2023 Zur Ausgabe